Acute hepatitis C: prevention and treatment

References

• National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology26(Suppl. 1), S2–S10 (1997).
   Web of Science ®Google Scholar
• Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet372(9635), 321–332 (2008).
   PubMed Web of Science ®Google Scholar
• Lorenz R, Endres S. Diagnosis and treatment of acute hepatitis C in adults. UpToDate Online 16.2.
   Google Scholar
• Kamal SM. Acute hepatitis C: a systematic review. Am. J. Gastroenterol.103(5), 1283–1297 (2008).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol.13(17), 2436–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis – United States, 2005. MMWR Surveill. Summ.56(3), 1–24 (2007).
   PubMedGoogle Scholar
• Spada E, Mele A, Ciccozzi M et al. Changing epidemiology of parenterally transmitted viral hepatitis: results from the hepatitis surveillance system in Italy. Dig. Liver Dis.33(9), 778–784 (2001).
   PubMedGoogle Scholar
• The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol.44(1), 20–29 (2004).
   PubMed Web of Science ®Google Scholar
• Desenclos JC. The challenge of hepatitis C surveillance in Europe. Euro. Surveill.8(5), 99–100 (2003).
   PubMedGoogle Scholar
• Sun CA, Chen HC, Lu SN et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J. Med. Virol.65(1), 30–34 (2001).
   PubMed Web of Science ®Google Scholar
• Okayama A, Stuver SO, Tabor E et al. Incident hepatitis C virus infection in a community-based population in Japan. J. Viral Hepat.9(1), 43–51 (2002).
   PubMed Web of Science ®Google Scholar
• Mohamed MK, Abdel-Hamid M, Mikhail NN et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology42(3), 683–687 (2005).
   PubMed Web of Science ®Google Scholar
• Zakaria S, Fouad R, Shaker O et al. Changing patterns of acute viral hepatitis at a major urban referral center in Egypt. Clin. Infect. Dis.44(4), e30–e36 (2007).
   PubMed Web of Science ®Google Scholar
• Meky FA, Stoszek SK, Abdel-Hamid M et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin. Infect. Dis.42(5), 628–633 (2006).
   PubMed Web of Science ®Google Scholar
• Akcam FZ, Uskun E, Avsar K, Songur Y. Hepatitis B virus and hepatitis C virus seroprevalence in rural areas of the southwestern region of Turkey. Int. J. Infect. Dis.13(2), 274–284 (2009).
   PubMed Web of Science ®Google Scholar
• Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur. J. Epidemiol.21(4), 299–305 (2006).
   PubMed Web of Science ®Google Scholar
• Afsar I, Gungor S, Sener AG, Yurtsever SG. The prevalence of HBV, HCV and HIV infections among blood donors in Izmir, Turkey. Indian J. Med. Microbiol.26(3), 288–289 (2008).
   PubMed Web of Science ®Google Scholar
• Bianco E, Stroffolini T, Spada E et al.; SEIEVA Collaborating Group. Case fatality rate of acute viral hepatitis in Italy: 1995–2000. An update. Dig. Liver Dis.35(6), 404–408 (2003).
   PubMedGoogle Scholar
• Hoofnagle JH, Carithers RL, Shapiro C, Ascher N. Fulminant hepatic failure: Summary of a workshop. Hepatology21(1), 240 (1995).
   PubMed Web of Science ®Google Scholar
• Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: Increased risk in chronic carriers of hepatitis B virus. Gut45(4), 613 (1999).
   PubMed Web of Science ®Google Scholar
• Vogt M, Lang T, Frösner G et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med.341(12), 866–870 (1999).
   PubMed Web of Science ®Google Scholar
• Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology33(2), 455–463 (2001).
   PubMed Web of Science ®Google Scholar
• Alter HJ, Conry-Cantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology26(3 Suppl. 1), S29–S33 (1997).
   Google Scholar
• Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA284(4), 450–456 (2000).
   PubMed Web of Science ®Google Scholar
• Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology29(3), 908–914 (1999).
   PubMed Web of Science ®Google Scholar
• Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol.31(Suppl. 1), 9–16 (1999).
   PubMed Web of Science ®Google Scholar
• Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J. Hepatol.49(4), 625–633 (2008).
   PubMed Web of Science ®Google Scholar
• Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology37(1), 60–64 (2003).
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology125(1), 80–88 (2003).
   PubMed Web of Science ®Google Scholar
• Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology47(1), 321–331 (2008).
   PubMed Web of Science ®Google Scholar
• Shata MT, Anthony DD, Carlson NL et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J. Viral Hepat.9(6), 400–410 (2002).
   PubMed Web of Science ®Google Scholar
• Klenerman P, Lucas M, Barnes E, Harcourt G. Immunity to hepatitis C virus: stunned but not defeated. Microbes Infect.4(1), 57–65 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol.158(3), 1473–1481 (1997).
   PubMed Web of Science ®Google Scholar
• Erickson AL, Houghton M, Choo QL et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J. Immunol.151(8), 4189–4199 (1993).
   PubMed Web of Science ®Google Scholar
• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat.13(1), 34–41 (2006).
   PubMed Web of Science ®Google Scholar
• Corey KE, Ross AS, Wurcel A et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin. Gastroenterol. Hepatol.4(10), 1278–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Jonas M. Children with hepatitis C. Hepatology36(Suppl. 1), S173–S178 (2002).
   Google Scholar
• Lehmann M, Meyer MF, Monazahian M et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J. Med. Virol.73(3), 387–391 (2004).
   PubMed Web of Science ®Google Scholar
• Bakr I, Rekacewicz C, El Hosseiny M et al. Higher clearance of hepatitis C virus infection in females compared with males. Gut55(8), 1183–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Wang C, Krantz E, Klarquist J et al. Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J. Infect. Dis.196(10), 1474–1482 (2007).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Turner B, He Q et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology43(4), 771–779 (2006).
   PubMed Web of Science ®Google Scholar
• Wells JT, Lucey MR, Said A. Hepatitis C in transplant recipients of solid organs, other than liver. Clin. Liver Dis.10(4), 901–917 (2006).
   PubMedGoogle Scholar
• Irshad M, Khushboo I, Singh S et al. Hepatitis C virus (HCV): a review of immunological aspects. Int. Rev. Immunol.27(6), 497–517 (2008).
   PubMed Web of Science ®Google Scholar
• Spengler U, Lechmann M, Irrgang B et al. Immune responses in hepatitis C virus infection. J. Hepatol.24(2 Suppl.), 20–25 (1996).
   PubMed Web of Science ®Google Scholar
• Chen M, Sällberg M, Sönnerborg A et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology116(1), 135–143 (1999).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature436, 946–952 (2005).
   PubMed Web of Science ®Google Scholar
• Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin. Immunol.128(2), 133–147 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai SL, Liaw YF, Chen MH et al. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology25, 449–458 (1997).
   PubMed Web of Science ®Google Scholar
• Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin. Liver Dis.7(1), 89–105 (2003).
   PubMedGoogle Scholar
• Rosen HR, Miner C, Sasaki AW et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology35, 190–198 (2002).
   PubMed Web of Science ®Google Scholar
• Missale G, Cariani E, Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Dig. Liver Dis.36(11), 703–711 (2004).
   PubMedGoogle Scholar
• Brinkmann V, Geiger T, Alkan S et al. Interferon α increases the frequency of interferon γ-producing human CD4+ T cells. J. Exp. Med.178, 1655–1663 (1993).
   PubMed Web of Science ®Google Scholar
• Luft T, Pang KC, Thomas E et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol.161, 1947–1953 (1998).
   PubMed Web of Science ®Google Scholar
• Rosen HR, Weston SJ, Im K et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology46, 350–358 (2007).
   PubMed Web of Science ®Google Scholar
• Randall G, Chen L, Panis M et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology131, 1584–1591 (2006).
   PubMed Web of Science ®Google Scholar
• Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology128, 1437–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Luby S, Khanani R, Zia M et al. Evaluation of blood bank practices in Karachi, Pakistan, and the government’s response. Health Policy Plan.15(2), 217–222 (2000).
   PubMed Web of Science ®Google Scholar
• Kapoor D, Saxena R, Sood B, Sarin SK. Blood transfusion practices in India: results of a national survey. Indian J. Gastroenterol.19(2), 64–67 (2000).
   PubMedGoogle Scholar
• Cruz JR, Pérez-Rosales MD, Zicker F, Schmunis GA. Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses. J. Clin. Virol.34(Suppl. 2), S75–S80 (2005).
   PubMedGoogle Scholar
• Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect. Dis.2(5), 293–302 (2002).
   PubMed Web of Science ®Google Scholar
• Hahn JA, Page-Shafer K, Lum PJ et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology34(1), 180–187 (2001).
   PubMed Web of Science ®Google Scholar
• Hutchinson SJ, Taylor A, Goldberg DJ et al. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990–1994: implications for control and prevention of blood-borne viruses. Addiction95(6), 931–940 (2000).
   PubMed Web of Science ®Google Scholar
• Maher L, Li J, Jalaludin B et al. High hepatitis C incidence in new injecting drug users: a policy failure? Aust. NZ J. Public Health31(1), 30–35 (2007).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Prevention of spread of hepatitis C. Hepatology36(5 Suppl. 1), S93–S98 (2002).
   PubMed Web of Science ®Google Scholar
• Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex. Transm. Infect.82(Suppl. 3), iii10–iii17 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore)74(4), 212–220 (1995).
   PubMed Web of Science ®Google Scholar
• Nguyen OK, Dore GJ, Kaldor JM et al.; ATAHC Protocol Steering Committee. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int. J. Drug Policy18(5), 447–451 (2007).
   PubMed Web of Science ®Google Scholar
• Frank C, Mohamed MK, Strickland GT et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet355(9207), 887–891 (2000).
   PubMed Web of Science ®Google Scholar
• Singh S, Dwivedi SN, Sood R, Wali JP. Hepatitis B, C and human immunodeficiency virus infections in multiply-injected kala-azar patients in Delhi. Scand. J. Infect. Dis.32(1), 3–6 (2000).
   PubMedGoogle Scholar
• Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ.77(10), 801–807 (1999).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Organ.77(10), 789–800 (1999).
   PubMed Web of Science ®Google Scholar
• Yildirim B, Tahan V, Ozaras R et al. Hepatitis C virus risk factors in the Turkish community. Dig. Dis. Sci.50(12), 2352–2355 (2005).
   PubMed Web of Science ®Google Scholar
• Tahan V, Karaca C, Yildirim B et al. Sexual transmission of HCV between spouses. Am. J. Gastroenterol.100(4), 821–824 (2005).
   PubMed Web of Science ®Google Scholar
• Mert A, Ozaras R, Tabak F, Tahan V, Akdogan M, Senturk H. Spouses of HCV carriers are not at serious risk. Scand. J. Infect. Dis.30(6), 644 (1998).
   PubMedGoogle Scholar
• Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm. Rep.47(RR-19), 1–39 (1998).
   PubMedGoogle Scholar
• Thomas DL, Zenilman JM, Alter HJ et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore – an analysis of 309 sex partnerships. J. Infect. Dis.171(4), 768–775 (1995).
   PubMed Web of Science ®Google Scholar
• Danta M, Brown D, Bhagani S et al.; HIV and Acute HCV (HAAC) Group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high risk sexual behaviours. AIDS21(8), 983–991 (2007).
   PubMed Web of Science ®Google Scholar
• Gambotti L, Batisse D, Colin-de-Verdiere N et al Acute Hepatitis C Collaborating Group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001–2004. Euro. Surveill.10(5), 115–117 (2005).
   PubMedGoogle Scholar
• Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA287(18), 2406–2413 (2002).
   PubMed Web of Science ®Google Scholar
• U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm. Rep.50(RR-11), 1–52 (2001).
   PubMedGoogle Scholar
• Chung H, Kudo M, Kumada T et al. Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel. J. Gastroenterol.38(9), 877–879 (2003).
   PubMed Web of Science ®Google Scholar
• De Carli G, Puro V, Ippolito G; Studio Italiano Rischio Occupazionale da HIV Group. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection31(Suppl. 2), 22–27 (2003).
   PubMed Web of Science ®Google Scholar
• Patel PR, Larson AK, Castel AD et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA296(16), 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Santantonio T, Medda E, Ferrari C et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin. Infect. Dis.43(9), 1154–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Martínez-Bauer E, Forns X, Armelles M et al.; Spanish Acute HCV Study Group. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J. Hepatol.48(1), 20–27 (2008).
   PubMed Web of Science ®Google Scholar
• Deterding K, Wiegand J, Grüner N et al. Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? J. Hepatol.48(6), 1019–1020 (2008).
   PubMed Web of Science ®Google Scholar
• Olmer M, Bouchouareb D, Zandotti C et al. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin. Nephrol.47(4), 263–270 (1997).
   PubMed Web of Science ®Google Scholar
• Minola E, Baldo V, Baldovin T et al. Intrafamilial transmission of hepatitis C virus infection. Eur. J. Epidemiol.21(4), 293–297 (2006).
   PubMed Web of Science ®Google Scholar
• Mohamed MK, Abdel-Hamid M, Mikhail NN et al. Intrafamilial transmission of hepatitis C in Egypt. Hepatology42(3), 683–687 (2005).
   PubMed Web of Science ®Google Scholar
• Tahan V, Yildirim B, Ture F et al. Anti-HCV seroprevalence in chronic HCV patients’ children in Turkey. J. Clin. Gastroenterol.38(1), 90–91 (2004).
   PubMed Web of Science ®Google Scholar
• Nomura H, Sou S, Tanimoto H et al. Short-term interferon-α therapy for acute hepatitis C: a randomized controlled trial. Hepatology39(5), 1213–1219 (2004).
   PubMed Web of Science ®Google Scholar
• Cox AL, Netski DM, Mosbruger T et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis.40(7), 951–958 (2005).
   PubMed Web of Science ®Google Scholar
• Moore A, Herrera G, Nyamongo J et al. Estimated risk of HIV transmission by blood transfusion in Kenya. Lancet358(9282), 657–660 (2001).
   PubMed Web of Science ®Google Scholar
• Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J. Hepatol.42(Suppl. 1), S108–S114 (2005).
   Google Scholar
• Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N. Engl. J. Med.325(2), 98–104 (1991).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology36(5 Suppl. 1), S65–S73 (2002).
   PubMedGoogle Scholar
• Espinosa M, Martin-Malo A, Alvarez de Lara MA et al. Natural history of acute HCV infection in hemodialysis patients. Clin. Nephrol.58, 143–150 (2002).
   PubMed Web of Science ®Google Scholar
• Engel M, Malta FM, Gomes MM et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health7, 50 (2007).
   PubMedGoogle Scholar
• Al-Harbi AS, Malik GH, Subaity Y et al. Treatment of acute hepatitis C virus infection with α interferon in patients on hemodialysis. Saudi J. Kidney Dis. Transpl.16, 293–297 (2005).
   PubMedGoogle Scholar
• Ozaras R, Yilmaz M, Mete B, Demirel A, Tahan V. Recognizing acute hepatitis C in hemodialysis patients. Dig. Dis. Sci.53(12), 3267–3268 (2008).
   PubMed Web of Science ®Google Scholar
• Myers RP, Regimbeau C, Thevenot T et al. Interferon for acute hepatitis C. Cochrane Database Syst. Rev.4, CD000369 (2009).
   Google Scholar
• National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Gastroenterology123(6), 2082–2099 (2002).
   PubMedGoogle Scholar
• Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology36(5 Suppl. 1), S195–S200 (2002).
   PubMed Web of Science ®Google Scholar
• Licata A, Di Bona D, Schepis F et al. When and how to treat acute hepatitis C? J. Hepatol.39(6), 1056–1062 (2003).
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Cornberg M, Wedemeyer H et al., German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon α-2b. N. Engl. J. Med.345(20), 1452–1457 (2001).
   PubMed Web of Science ®Google Scholar
• Rocca P, Bailly F, Chevallier M et al. Early treatment of acute hepatitis C with interferon α-2b or interferon α-2b plus ribavirin: study of sixteen patients. Gastroenterol. Clin. Biol.27(3 Pt 1), 294–299 (2003).
   PubMedGoogle Scholar
• Takano S, Satomura Y, Omata M. Effects of interferon β on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology107(3), 805–811 (1994).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Ismail A, Graham CS et al. Pegylated interferon a therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology39, 1721–1731 (2004).
   PubMed Web of Science ®Google Scholar
• Dominguez S, Ghosn J, Valantin MA et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS20(8), 1157–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Calleri G, Cariti G, Gaiottino F et al. A short course of pegylated interferon-α in acute HCV hepatitis. J. Viral Hepat.14, 116–121 (2007).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Fouly AE, Kamel RR et al. Peginterferon α-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology130(3), 632–638 (2006).
   PubMed Web of Science ®Google Scholar
• Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon α-2b for acute hepatitis infection: the HEP-NET acute-HCV-II study. Hepatology43(2), 250–256 (2006).
   PubMed Web of Science ®Google Scholar
• Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology43(5), 923–931 (2006).
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Bargiacchi O, Audagnotto S et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon α-2b treatment for acute hepatitis C. J. Antimicrob. Chemother.57(2), 360–363 (2006).
   PubMed Web of Science ®Google Scholar
• Broers B, Helbling B, Francois A et al. Swiss Association for the Study of the Liver (SASL 18). Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J. Hepatol.42(3), 323–328 (2005).
   PubMed Web of Science ®Google Scholar